A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Others
| A053.23 | Differential rotenone and | 1-methyl-4-phenylpyridinium ion toxicity | |
| A090.27 | uence of a potential antiaddiction compound, | 1-methyl-tetrahydroisoquinoline, on coca | |
| A164.10 | Generation of two recombinant | 129X1/SvJ mouse substrains selected for | |
| A107.1 | 15-deoxyDelta-12, | 14-prostaglandin J2 promotes astroglial | |
| A107.1 | 15-deoxyDelta-12, 14-prostaglandin J2 pr | ||
| A225.5 | in the rat somatosensory cortex imaged with | 2-deoxyglucose and fMRI | |
| A007.4 | Mapping the brain with | 2-deoxyglucose during classical conditio | |
| A007.12 | vation during a radial maze task: a detailed | 2-deoxyglucose study | |
| A225.10 | cations of cellular properties combined with | 2-photon targeted patching for the study | |
| A088.9 | gene interactions and the development of the | 22q11-associated schizophrenia | |
| A152.20 | Benzodiazepine- and serotonin | 2A-receptors modulate the aversive effec | |
| A218.5 | 2P domain K+ channels are modulated by G | ||
| A230.11 | : a fluoro-jade B study of the effects of 3, | 3’-iminodipropionitrile (IDPN), allylnit | |
| A065.1 | xity and physiological implications of 5'and | 3'ACHE splice variants | |
| A154.9 | mRNA regulation via | 3’UTRs: an examination of PSD-95 and oth | |
| A014.27 | Synaptic integration in a | 3-compartment model of layer 5 pyramidal | |
| A089.17 | mpus: a quantitative electron microscopy and | 3-dimensional reconstruction study | |
| A054.5 | neuronal apoptosis in a phosphatidylinositol | 3-kinase-dependent Bad phosphorylation m | |
| A150.1 | Systemic administration of | 3-nitropropionic acid potentiates memory | |
| A020.21 | cution unmasks latent motor impairments in a | 3-nitropropionic acid subchronic treatme | |
| A020.28 | Neural stem cell transplantation in the | 3-nitroproprionic acid model of Huntingt | |
| A080.19 | of pH effects on GABA-A receptor-associated | 35S-tert-butylbicyclophosphorothionate b | |
| A229.8 | RU | 38486 influences expression of glycoprot | |
| A075.6 | roid hormone on sodium current densities and | 3[H]-Oubain binding sites in neuronal ce | |
| A121.9 | 4-Aminopyridine amplifies tetrodotoxin-r | ||
| A093.4 | 4-aminopyridine restores visual ocular-m | ||
| A230.11 | ile (AN), cis-crotononitrile (cis-CN) and 2, | 4-hexadienenitrile (HDN) on the CNS of t | |
| A219.2 | 3, | 4-methylenedioxy-methamphetamine (MDMA) | |
| A077.15 | Effects of modafinil on the | 5-choice serial reaction time test, a ro | |
| A048.13 | hips between frontal cortex and dorsal raphe | 5-HT neurons | |
| A164.1 | Stimulation of | 5-HT neurons in the median raphe nucleus | |
| A126.9 | show evidence of region-specific changes in | 5-HT neurotransmission | |
| A205.4 | Actions of | 5-HT on prefrontal neurons: role in psyc | |
| A219.6 | Electrophysiological analysis of | 5-HT receptor function in a rat model of | |
| A091.8 | 5-HT receptor subtypes in the rat centra | ||
| A225.2 | Endogenous | 5-HT released from thalamic axons induce | |
| A213.1 | population in the mouse spinal cord via the | 5-HT1 receptor family | |
| A219.1 | Role of the C-terminal domain of | 5-HT1A and 5-HT1B receptors in their pla | |
| A164.20 | 5-HT1A and 5-HT2 receptors of the dorsal | ||
| A234.9 | selective serotonin reuptake inhibitor - on | 5-HT1A and 5-HT2A receptors in isolation | |
| A219.15 | Fluoxetine internalizes | 5-HT1A autoreceptors and reduces the in | |
| A219.3 | n the cognitive deficit induced by serotonin | 5-HT1A receptor activation | |
| A089.1 | 5-HT1A receptor activation counteracts c | ||
| A234.5 | In vivo evidence that | 5-HT1A receptor activation increases Fos | |
| A088.2 | 5-HT1A receptor knockout mice display al | ||
| A086.8 | prefrontal cortex by exogenous activation of | 5-HT1A receptors | |
| A126.2 | Desensitisation of rat serotonin | 5-HT1A receptors by chronic administrati | |
| A219.7 | Differential activation by human | 5-HT1A receptors of ion currents in Xeno | |
| A219.12 | Ultrastructural localisation of serotonin | 5-HT1B receptors with the glutamate rece | |
| A219.5 | Effect of 50 Hz magnetic fields on the | 5-HT1B serotoninergic receptor: a replic | |
| A084.19 | 5-HT2 receptor activation following acut | ||
| A126.4 | ation of the SSRI augmentation properties of | 5-HT2 receptor antagonists using in vivo | |
| A086.3 | socortical dopaminergic system by prefrontal | 5-HT2 receptors. Reversal by antipsychot | |
| A232.8 | Co-localisation of serotonin | 5-HT2A and CB1 cannabinoid receptors wit | |
| A051.13 | Mutant mice which do not express | 5-HT2A receptors exhibit reduced formali | |
| A232.3 | G-protein coupling at | 5-HT2a receptors: scintillation proximit | |
| A217.4 | 5-HT3 receptor agonism inhibits hippocam | ||
| A232.7 | rons in the medial prefrontal cortex through | 5-HT3 receptors | |
| A127.3 | tion. Functional interaction between NK1 and | 5-HT3 receptors in the nucleus tractus s | |
| A219.16 | cs are potent antagonists of homomeric human | 5-HT3A gated calcium transients | |
| A219.2 | the CA1 excitatory neurotransmission through | 5-HT4 receptor activation | |
| A219.17 | 5-HT4 receptor partial agonists increase | ||
| A219.4 | A proteomic analysis reveals that | 5-HT4 receptor splice variants with diff | |
| A115.6 | te as 3, 4N-methylenedioxymethamphetamine: a | 5-HT4 receptors control | |
| A049.8 | Serotonin | 5-HT4 receptors regulate long-term depre | |
| A126.5 | 5-HT6 receptor-selective upregulation of | ||
| A114.2 | Acute effects of SB-269970, a selective | 5-HT7 receptor antagonist, on isolation- | |
| A040.3 | ogenesis in serotonin transporter deficient ( | 5-HTTKO) mice | |
| A126.9 | Mice that over-express the | 5-hydroxytryptamine transporter show evi | |
| A021.24 | Role of ryanodine and inositol 1, 4, | 5-triphosphate receptors in the neurotox | |
| A053.20 | eneration of dopaminergic neurons induced by | 6-hydroxydopamine | |
| A107.20 | 6-Hydroxydopamine (6-OHDA) -induced lesi | ||
| A019.3 | Effects of unilateral | 6-hydroxydopamine lesions on aminopeptid | |
| A053.22 | -synuclein expression in rat brain following | 6-hydroxydopamine nigrostriatal lesions | |
| A121.8 | Neurokinin-1 receptor antagonist inhibits | 6-hydroxydopamine-induced plasma leakage | |
| A053.7 | fects of the agonist CHPG in the striatum of | 6-hydroxydopamine-lesioned rats: possibl | |
| A019.7 | on substantia nigra pars compacta (SNpc) on | 6-OH-dopamine lesioned rats | |
| A092.14 | perpolarizations of subthalamic neurons from | 6-OHDA lesioned and non-lesioned rats | |
| A147.15 | ells and function after transplantation into | 6-OHDA lesioned rats | |
| A053.14 | tion of the l-dopa-induced dyskinesia in the | 6-OHDA model and evaluation of the effec | |
| A092.10 | of acute or chronic L-Dopa treatment on the | 6-OHDA rat model of Parkinson's disease: | |
| A112.16 | or gating and decreased latent inhibition in | 6-OHDA-lesioned rats | |
| A048.7 | ronal striatal cultures after exposure to 7, | 8-styrene oxide |
Top -